Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02299089 · OUTCOME

CAM2029 Effect on Growth Hormone (GH) (Acromegaly)

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) · Source last updated 2017-12-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Day 84

What was measured

GH (growth hormone) levels measured on Day 84 in patients with acromegaly

Analysis population: Pharmacokinetic population (5 acromegaly patients)

Groups in this outcome

CAM2029 10 mg q2w (Acromegaly)

CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot

CAM2029 20 mg q4w (Acromegaly)

CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CAM2029 10 mg q2w (Acromegaly)3
CAM2029 20 mg q4w (Acromegaly)2

Reported measurements

GH level < 2.5 μg/L
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
CAM2029 10 mg q2w (Acromegaly)2Not reportedNot reportedNot reportedNot reported
CAM2029 20 mg q4w (Acromegaly)2Not reportedNot reportedNot reportedNot reported
GH level >2.5 μg/L
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
CAM2029 10 mg q2w (Acromegaly)1Not reportedNot reportedNot reportedNot reported
CAM2029 20 mg q4w (Acromegaly)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        2
    title
    GH level < 2.5 μg/L
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    GH level >2.5 μg/L
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      2
    units
    Participants
description
GH (growth hormone) levels measured on Day 84 in patients with acromegaly
groups
  1. description
    CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
    id
    OG000
    title
    CAM2029 10 mg q2w (Acromegaly)
  2. description
    CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
    id
    OG001
    title
    CAM2029 20 mg q4w (Acromegaly)
param Type
NUMBER
population Description
Pharmacokinetic population (5 acromegaly patients)
reporting Status
POSTED
time Frame
Day 84
title
CAM2029 Effect on Growth Hormone (GH) (Acromegaly)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice